Heron Therapeutics Competitors

Heron Therapeutics (NASDAQ:HRTX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Heron Therapeutics and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

Heron Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Earnings & Valuation

This table compares Heron Therapeutics and Ionis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Ionis Pharmaceuticals has higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Heron Therapeutics and Ionis Pharmaceuticals, as provided by MarketBeat.com.

Heron Therapeutics presently has a consensus price target of $26.00, suggesting a potential upside of 43.81%. Ionis Pharmaceuticals has a consensus price target of $57.4545, suggesting a potential upside of 35.31%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Ionis Pharmaceuticals.

Summary

Ionis Pharmaceuticals beats Heron Therapeutics on 8 of the 14 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Comparatively, 13.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Heron Therapeutics and TG Therapeutics' net margins, return on equity and return on assets.

Risk & Volatility

Heron Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500.

Valuation and Earnings

This table compares Heron Therapeutics and TG Therapeutics' revenue, earnings per share and valuation.

TG Therapeutics has lower revenue, but higher earnings than Heron Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Heron Therapeutics and TG Therapeutics, as provided by MarketBeat.

Heron Therapeutics currently has a consensus price target of $26.00, suggesting a potential upside of 43.81%. TG Therapeutics has a consensus price target of $63.3333, suggesting a potential upside of 54.13%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Heron Therapeutics.

Summary

TG Therapeutics beats Heron Therapeutics on 8 of the 14 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Comparatively, 44.8% of Allakos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Heron Therapeutics and Allakos' net margins, return on equity and return on assets.

Risk & Volatility

Heron Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Valuation and Earnings

This table compares Heron Therapeutics and Allakos' revenue, earnings per share and valuation.

Allakos has lower revenue, but higher earnings than Heron Therapeutics. Allakos is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Heron Therapeutics and Allakos, as provided by MarketBeat.

Heron Therapeutics currently has a consensus price target of $26.00, suggesting a potential upside of 43.81%. Allakos has a consensus price target of $181.50, suggesting a potential upside of 69.37%. Given Allakos' stronger consensus rating and higher possible upside, analysts plainly believe Allakos is more favorable than Heron Therapeutics.

Summary

Allakos beats Heron Therapeutics on 8 of the 12 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Comparatively, 0.3% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Heron Therapeutics and Perrigo's net margins, return on equity and return on assets.

Risk & Volatility

Heron Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Valuation and Earnings

This table compares Heron Therapeutics and Perrigo's revenue, earnings per share and valuation.

Perrigo has higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Heron Therapeutics and Perrigo, as provided by MarketBeat.

Heron Therapeutics currently has a consensus price target of $26.00, suggesting a potential upside of 43.81%. Perrigo has a consensus price target of $52.00, suggesting a potential upside of 21.98%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Heron Therapeutics is more favorable than Perrigo.

Summary

Heron Therapeutics beats Perrigo on 8 of the 14 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Heron Therapeutics and Sarepta Therapeutics' net margins, return on equity and return on assets.

Risk & Volatility

Heron Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500.

Valuation and Earnings

This table compares Heron Therapeutics and Sarepta Therapeutics' revenue, earnings per share and valuation.

Heron Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Heron Therapeutics and Sarepta Therapeutics, as provided by MarketBeat.

Heron Therapeutics currently has a consensus price target of $26.00, suggesting a potential upside of 43.81%. Sarepta Therapeutics has a consensus price target of $150.3810, suggesting a potential upside of 110.68%. Given Sarepta Therapeutics' higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than Heron Therapeutics.

Summary

Sarepta Therapeutics beats Heron Therapeutics on 8 of the 14 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent ratings for Heron Therapeutics and Blueprint Medicines, as provided by MarketBeat.

Heron Therapeutics currently has a consensus price target of $26.00, suggesting a potential upside of 43.81%. Blueprint Medicines has a consensus price target of $112.40, suggesting a potential upside of 19.07%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Heron Therapeutics is more favorable than Blueprint Medicines.

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Comparatively, 3.8% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Heron Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Heron Therapeutics and Blueprint Medicines' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Heron Therapeutics and Blueprint Medicines' revenue, earnings per share and valuation.

Heron Therapeutics has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Heron Therapeutics beats Blueprint Medicines on 8 of the 15 factors compared between the two stocks.